Clinical trials
DLBCL clinical trials
Below are recruiting dlbcl clinical trials, each written for real people, not researchers. We’re tracking 153 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03936153RecruitingPhase 2
Oral abexinostat for relapsed lymphoma after two prior treatments
This Phase 2 study tests how well and how safely an oral medicine called abexinostat works for people with diffuse large B-cell lymphoma that has come back or did not respond to the last treatment. It may help by shrinking lymphoma and controlling the disease using a medication taken by mouth.
BeijingAges 18 years+ - NCT07070648Recruiting
Predicting DLBCL treatment response with ctDNA and PET scans
This trial uses a blood test (ctDNA) and PET scans to predict how well standard first-line treatment works for diffuse large B-cell lymphoma (DLBCL). It aims to find out if these tests can guide better care.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07057765Recruiting
Blood markers for predicting DLBCL treatment response
This study looks at how certain blood tests (like CRP, albumin, and their ratios) might help predict how well treatment works for newly diagnosed DLBCL. If you are getting R-CHOP, this trial could help doctors better understand your response to therapy.
Cairo, Cairo GovernorateAges 18–65 - NCT06846463RecruitingPhase 2
Zanubrutinib for DLBCL with specific genetic changes
This trial tests a targeted drug called zanubrutinib combined with standard chemotherapy (R-CHOP) for people with DLBCL who have specific genetic changes in their tumor. The goal is to see if adding this drug can improve outcomes.
Richmond, VirginiaAges 18 years+ - NCT06828991RecruitingPhase 2
Mosunetuzumab for older DLBCL patients with residual ctDNA
This trial tests whether adding a targeted immunotherapy drug called mosunetuzumab after standard chemotherapy can help older adults with DLBCL who still have tiny traces of cancer DNA in their blood. If you qualify, the goal is to reduce the chance of the cancer coming back.
Rochester, New YorkAges 70 years+ - NCT06682130RecruitingPhase 2
Glofitamab before stem cell transplant for relapsed DLBCL
This study tests a drug called glofitamab before a stem cell transplant for people whose DLBCL has come back or not responded after at least two prior treatments. The goal is to see if this combination can help control the lymphoma before the transplant.
Suzhou, JiangsuAges 18–70 - NCT06736613RecruitingPhase 2
Blood test for tumor DNA in high-risk B-cell lymphoma
This trial uses a blood test to look for tumor DNA in people with high-risk B-cell lymphoma, to help predict if the lymphoma might spread to the brain or spinal cord. It may help doctors decide on extra treatments to prevent that spread.
Basking Ridge, New JerseyAges 18 years+ - NCT06481826Recruiting
Glofitamab for Chinese patients with relapsed or refractory DLBCL
This trial tests a drug called glofitamab for people with a type of lymphoma (DLBCL) that has come back or not responded to at least two prior treatments. The goal is to see if this drug can help shrink tumors or stop the disease from progressing.
Beijing, Beijing MunicipalityAges 18–80 - NCT06050694RecruitingPhase 2
Testing glofitamab plus chemo for untreated DLBCL
This trial tests a new drug called glofitamab combined with standard Pola-R-CHP chemotherapy for people with untreated DLBCL. The goal is to see if using PET scans and blood tests early on can guide treatment and improve outcomes.
Toronto, OntarioAges 18 years+ - NCT05836896RecruitingPhase 1
Safety check of BCMA CAR T-cells made from your own immune cells
This early-phase trial tests whether a personalized BCMA-targeting CAR T-cell treatment is safe and what dose is tolerable in people whose lymphoma or myeloma has come back or did not respond to prior treatment. If you qualify, the team will monitor you closely for side effects to find the safest maximum tolerated dose.
DresdenAges 18 years+ - NCT07878351Recruiting
Blood test to guide treatment for large B-cell lymphoma
This study looks at whether a blood test can help doctors understand and monitor large B-cell lymphoma during treatment. It may help guide decisions about your care.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07012980RecruitingPhase 2
Three-drug combination for first-line lymphoma in people 70 and older
This study tests a combination of three newer targeted drugs for older adults (70+) who have just been diagnosed with diffuse large B-cell lymphoma and have not yet received any treatment. The goal is to see if this drug combo can control the lymphoma effectively while being manageable for older patients.
Shanghai, Shanghai MunicipalityAges 70 years+ - NCT06717347RecruitingPhase 3
Study of a new drug combo for untreated DLBCL
This trial tests whether adding zilovertamab vedotin to standard chemo (R-CHP) works better than standard chemo (R-CHOP) for people with untreated diffuse large B-cell lymphoma (DLBCL). It aims to find a more effective treatment option.
Mobile, AlabamaAges 18 years+ - NCT07424833RecruitingPhase 1
Study of APG-3288 for Relapsed/Refractory Blood Cancers
This trial is testing a new drug called APG-3288 for people with certain relapsed or treatment-resistant blood cancers (like CLL/SLL, DLBCL, MCL, WM, MZL, or FL). You may qualify if you've tried at least 2 prior treatments and are looking for a new option.
Los Angeles, CaliforniaAges 18 years+ - NCT03494296Recruiting
Low-dose decitabine plus COP for relapsed lymphoma
This trial studies whether a low-dose chemotherapy medicine (decitabine) combined with a COP chemotherapy regimen can help adults whose diffuse large B-cell lymphoma (DLBCL) has come back or did not respond to treatment. It may be an option if you have measurable disease and can meet key safety and health requirements.
Harbin, HeilongjiangAges 18 years+ - NCT03356054RecruitingPhase 1/Phase 2
Test drug for CD30-positive lymphoma after first treatment fails
This early-phase study tests a lymphoma treatment in adults whose diffuse large B-cell lymphoma (DLBCL) is “CD30-positive” and who didn’t respond well to first-line chemotherapy (like R-CHOP) or had an early relapse. It aims to see if the treatment can shrink the lymphoma and is safe enough to move forward.
RotterdamAges 18 years+ - NCT03869619Recruiting
Real-life data study for adults with recent lymphoma
This study collects “real-world” health information about adults whose lymphoma was diagnosed within the last 6 months. It aims to better understand lymphoma types and how patients do over time, using data from everyday care rather than testing a new drug.
ArrasAges 18 years+ - NCT04502394RecruitingPhase 1/Phase 2
Investigational drug combo for relapsed blood cancer
This trial combines two investigational drugs to see if they are safe and effective for patients with two types of blood cancer: diffuse large B-cell lymphoma (DLBCL) or chronic lymphocytic leukemia (CLL) that has come back or stopped responding to standard treatments. It may offer a new option when other treatments have not worked.
Goshen, IndianaAges 18 years+ - NCT05659628RecruitingPhase 1
CD19 CAR-T plus PD-1 antibody for relapsed lymphoma
This Phase 1 study tests a new type of immune cell therapy (CD19 CAR-T) combined with an anti–PD-1 drug for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It aims to improve cancer control when standard treatments have not worked or the cancer has come back.
Hangzhou, ZhejiangAges 18–75 - NCT05831865Recruiting
Testing best first-line stem cell transplant for aggressive lymphoma
This trial studies the best way to use an early (frontline) stem cell transplant for high-risk, CD20-positive diffuse large B-cell lymphoma (DLBCL). It aims to improve outcomes by comparing treatment approaches designed for people with a higher risk score.
Beijing, Beijing MunicipalityAges 18–70 - NCT06176729RecruitingPhase 2
Pola-R2 for older, less fit adults with new DLBCL
This trial tests a combination of three drugs (pola, Rituxan, and lenalidomide) for older adults (70+) with a common type of lymphoma (DLBCL) who are not well enough for standard chemotherapy. The goal is to see if this gentler treatment works well for patients who are less fit.
Beijing, Beijing MunicipalityAges 70 years+ - NCT06299553Recruiting
Study of tafasitamab with lenalidomide for relapsed DLBCL patients
This study looks at how well a combination of two drugs, tafasitamab and lenalidomide, works for people with a type of lymphoma (DLBCL) that has come back or hasn't responded to treatment. After the combination, patients continue with tafasitamab alone. This is for patients who cannot have a stem cell transplant.
MilanAges 18 years+ - NCT06086197RecruitingPhase 2
A drug combo for early relapsed or refractory DLBCL
This trial tests a combination of chemotherapy drugs for people with a type of lymphoma called diffuse large B-cell lymphoma that has either come back early or never fully responded to first treatment. The goal is to see if this drug combination can help control the lymphoma.
Hangzhou, ZhejiangAges 18 years+ - NCT07817641Recruiting
Proton therapy for lymphoma in the chest
This trial tests proton therapy, a precise type of radiation, to treat lymphoma in the chest. The goal is to reduce damage to healthy organs while still curing the cancer.
Copenhagen, Select A StateAges 18 years+
Hear when a new DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for dlbcl?
- Yes. Clin2 currently lists 153 recruiting dlbcl studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a dlbcl trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a dlbcl trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.